Alembic Pharmaceuticals profit and loss

Latest FY26

Revenue: ₹7,345cr+10.1% on FY25
EBITDA: ₹1,118cr+10.9% on FY25
Net profit: ₹671cr+15.3% on FY25
EPS: ₹34.33+15.7% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	7,784	7,345	6,672	6,229	5,653	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	62.8	54.4	42.6	28.3	2.7
	7,847	7,399	6,715	6,257	5,655
	1,833	1,747	1,672	1,403	1,250
	520	509	411	455	380
	−157	−272	−290	−143	78.6
	1,783	1,732	1,562	1,446	1,169
	97.7	93.6	78.8	56.2	50.2
	342	319	279	273	275
	2,635	2,510	2,308	2,134	2,066
	7,055	6,639	6,021	5,624	5,270
	1,169	1,118	1,008	933	708
	826	800	730	661	433
Profit
	792	761	693	633	386
	−67.0	−67.0	12.9	0.0	0.0
	725	694	706	633	386
	150	128	122	62.1	3.4
	−114	−104	3.0	−46.1	9.2
	36.1	23.1	125	16.0	12.6
	1.1	0.2	0.9	−1.0	−30.9
	690	671	582	616	342
	688	671	581	617	373
	26.4	24.9	5.5	−10.8	13.4
	716	696	588	605	355
	—	675	583	616	342
	−1.6	3.9	−1.4	0.0	0.0
Per share
	₹35.27	₹34.33	₹29.68	₹31.33	₹17.40
	₹35.27	₹34.33	₹29.68	₹31.33	₹17.40
Other comprehensive income — detail
	26.4	24.9	5.5	—	—
	−7.0	−7.0	−1.9	−15.6	−0.3
	−1.0	−0.9	−0.8	−1.0	—
	—	—	—	−1.0	0.0
	32.9	30.9	6.6	3.8	13.7
	0.5	0.0	0.0	—	—
	504	—	589	605	355
	212	—	−1.4	0.0	0.0
Per share — as-filed variants
	₹35.27	₹34.33	₹29.68	₹31.33	₹17.40
	₹35.27	₹34.33	₹29.68	₹31.33	₹17.40
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	5,587	5,360	4,879	4,514	3,944
	71.8%	73.0%	73.1%	72.5%	69.8%
Adjusted (ex-exceptional items) — derived
	792	761	693	633	386
	−67.0	−67.0	12.9	0.0	0.0
	753	736	571	616	342
	₹38.53	₹37.64	₹29.14	₹31.33	₹17.40

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

APLLTD₹764.90

Alembic Pharmaceuticals Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersAJANTPHARM IPCALAB TORNTPHARM ALIVUS AKUMS AGARWALEYE ADVENZYMES AARTIPHARMMcap ₹15,034 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	5,652.6	6,228.6	6,672.1	7,344.9	7,784.0
Other Income	2.7	28.3	42.6	54.4	62.8
Total Income	5,655.4	6,256.9	6,714.6	7,399.3	7,846.8
Expenses
+ Cost of Materials Consumed	1,250.1	1,403.0	1,672.2	1,747.4	1,833.4
+ Purchases of Stock-in-Trade	380.1	454.9	411.0	508.9	520.2
+ Changes in Inventories	78.6	-142.8	-289.8	-271.8	-156.5
+ Employee Benefit Expense	1,169.1	1,446.3	1,562.3	1,731.9	1,783.1
+ Finance Costs	50.2	56.2	78.8	93.6	97.7
+ Depreciation & Amortisation	275.4	272.7	278.6	318.6	342.5
+ Other Expenses	2,066.3	2,133.9	2,308.2	2,510.1	2,634.8
Total Expenses	5,269.9	5,624.1	6,021.2	6,638.6	7,055.2
EBITDA	708.4	933.4	1,008.2	1,118.5	1,169.0
EBIT	432.9	660.7	729.7	799.9	826.5
Profit
PBT before Exceptional Items	385.5	632.8	693.4	760.7	791.6
+ Exceptional Items	0.0	0.0	12.9	-67.0	-67.0
Pretax Income	385.5	632.8	706.3	693.7	724.6
+ Current Tax	3.4	62.1	122.2	127.6	149.7
+ Deferred Tax	9.2	-46.1	3.0	-104.5	-113.6
Tax Expense	12.6	16.0	125.2	23.1	36.1
+ Share of Associates & JVs	-30.9	-1.0	0.9	0.2	1.1
Net Income	342.0	615.8	582.0	670.8	689.6
+ Net Income — Continuing Ops	372.9	616.8	581.1	670.6	688.5
+ Other Comprehensive Income	13.4	-10.8	5.5	24.9	26.4
Total Comprehensive Income	355.4	605.0	587.5	695.7	716.0
Net Income to Common	342.0	615.8	583.4	674.8	—
Minority Interest	0.0	0.0	-1.4	3.9	-1.6
Per Share
Basic EPS	17.40	31.33	29.68	34.33	35.27
Diluted EPS	17.40	31.33	29.68	34.33	35.27
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	5.5	24.9	26.4
+ Items NOT to be Reclassified to P&L	-0.3	-15.6	-1.9	-7.0	-7.0
+ Tax on Items NOT to be Reclassified	—	-1.0	-0.8	-0.9	-1.0
+ Tax on Items NOT to be Reclassified — alt tag	0.0	-1.0	—	—	—
+ Items to be Reclassified to P&L	13.7	3.8	6.6	30.9	32.9
+ Tax on Items to be Reclassified	—	—	0.0	0.0	0.5
Comprehensive Income — Owners of Parent	355.4	605.0	589.0	—	504.3
Comprehensive Income — Non-controlling Interests	0.0	0.0	-1.4	—	211.7
Per Share — as-filed variants
Basic EPS — Continuing Operations	17.40	31.33	29.68	34.33	35.27
Diluted EPS — Continuing Operations	17.40	31.33	29.68	34.33	35.27
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	3,943.8	4,513.5	4,878.7	5,360.5	5,586.8
Gross Margin %	69.77	72.46	73.12	72.98	71.77
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	385.5	632.8	693.4	760.7	791.6
− Exceptional Items (reconciliation)	0.0	0.0	12.9	-67.0	-67.0
Net Income Adj (tax-effected)	342.0	615.8	571.4	735.6	753.2
EPS Adj	17.40	31.33	29.14	37.64	38.53
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	2.00	2.00	2.00	2.00	2.00
Filed Debt Equity	0.00	0.00	0.23	0.24	0.28
Filed Dscr	—	—	9.98	6.91	7.63
Filed Iscr	—	—	9.98	8.41	9.04
Paid Up Equity Capital	39.3	39.3	39.3	39.3	39.3

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.